Previous 10 | Next 10 |
Immix Biopharma ( NASDAQ: IMMX ) on Friday said it had got an approval from an institutional review board to enroll children in its upcoming clinical trial of its IMX-110 therapy for the treatment of rhabdomyosarcoma. Rhabdomyosarcoma is a rare type of cancer that forms i...
Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”) While their future value is uncertain, PRVs are transferable to other companies and have historically sold for $67 to $350 million according to a...
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa LOS ANGELES, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, ...
California Soft Tissue Sarcoma Site to lead expanded clinical site consortium Historically, high-enrolling lead site has enrolled 2-3 patients per month Clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT sca...
Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tum...
Gainers: Bluejay Diagnostics BJDX +29%. DBV Technologies DBVT +12%. Arcellx (ACLX) +10%. Immix Biopharma (IMMX) +10%. AbCellera Biologics (ABCL) +8%. Losers: Precision BioSciences (DTIL) -10%. Blueprint Medicines (BPMC) -9%. Hutchmed (China) (HCM)&...
Gainers: Immix Biopharma (IMMX) +37%. Bright Green (BGXX) +29%. Repare Therapeutics (RPTX) +29%. Yumanity Therapeutics (YMTX) +24%. PDS Biotechnology (PDSB) +15%. Losers: Zosano Pharma (ZSAN) -48%. Immunic (IMUX) -41%. Aeglea BioTherapeutics (AGLE) -40%...
Immix Biopharma (IMMX) +37%. Repare Therapeutics RPTX +28% on signing licensing deal with Repare Therapeutics for tumor candidate. Chewy CHWY +20% on Q1 results. UiPath PATH +12% on Q1 results. Blue Apron Holdings APRN +11% after launch of meal kits on ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CASI Pharmaceuticals (NASDAQ: CASI ) stock tops out pre-market gainers. Immunic (NASDAQ: IMUX ) stock leads our pre-market losers. Several stocks are pulling back after rallies yesterday. Source: f11ph...
Gainers: TherapeuticsMD (TXMD) +361%. JanOne (JAN) +70%. Houston American Energy (HUSA) +57%. CatchMark Timber Trust (CTT) +44%. Mullen Automotive (MULN) +43%. Gogoro (GGR) +37%. BlackSky Technology (BKSY) +32%. Cassava Sciences (SAVA) +25%. MicroStrategy (MSTR) +24%. NexImmune (NEXI) +23%. L...
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and...
Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Timing of milestone in-line with mid-2024 guidance Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...